Tech Company Financing Transactions
GenEdit Funding Round
Bow Capital, Company K Partners and Data Collective participated in a $26 million funding round for GenEdit. The round was announced on 9/27/2021.
Transaction Overview
Company Name
Announced On
9/27/2021
Transaction Type
Venture Equity
Amount
$26,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The funding will support the further development of GenEdit's NanoGalaxy platform of non-viral, non-lipid polymer nanoparticles, and the selection for clinical development of therapeutic candidates targeting diseases of the nervous system.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
681 Gateway Blvd. 3rd Foor
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
GenEdit is a next-generation genome editing company. We are developing non-viral delivery technologies for the CRISPR/Cas9 gene editing system that can safely and efficiently correct gene mutations in patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kunwoo Lee
Chief Financial Officer
Aaron Mishel
Chief Scientific Officer
Romuald Corbau
Chief Technical Officer
Timothy Fong
Vice President
Yvonne Angell
Vice President
Derek Sloan
VP - Bus. Development
Jennifer Cygan
VP - Operations
Hyo Park
Browse more venture capital transactions:
Prev: 9/27/2021: Syng venture capital transaction
Next: 9/27/2021: Elligo Health Research venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs